tradingkey.logo
tradingkey.logo
Search

AnaptysBio Inc

ANAB
Add to Watchlist
60.870USD
+2.390+4.09%
Market hours ETQuotes delayed by 15 min
1.68BMarket Cap
LossP/E TTM

TradingKey Stock Score of AnaptysBio Inc

Currency: USD Updated: 2026-06-24

Key Insights

AnaptysBio Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 16 out of 388 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 88.80.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

AnaptysBio Inc's Score

Industry at a Glance

Industry Ranking
16 / 388
Overall Ranking
57 / 4571
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

AnaptysBio Inc Highlights

StrengthsRisks
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 1267.39% year-on-year.
Undervalued
The company’s latest PE is -57.34, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 29.21M shares, decreasing 29.73% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 13.46K shares of this stock.

Analyst Rating

Based on 11 analysts
Buy
Current Rating
88.800
Target Price
+54.41%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

How does TradingKey generate the Stock Score of AnaptysBio Inc?

The TradingKey Stock Score provides a comprehensive assessment of AnaptysBio Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of AnaptysBio Inc’s performance and outlook.

How do we generate the financial health score of AnaptysBio Inc?

To generate the financial health score of AnaptysBio Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects AnaptysBio Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of AnaptysBio Inc.

How do we generate the company valuation score of AnaptysBio Inc?

To generate the company valuation score of AnaptysBio Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare AnaptysBio Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of AnaptysBio Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of AnaptysBio Inc.

How do we generate the earnings forecast score of AnaptysBio Inc?

To calculate the earnings forecast score of AnaptysBio Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on AnaptysBio Inc’s future.

How do we generate the price momentum score of AnaptysBio Inc?

When generating the price momentum score for AnaptysBio Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of AnaptysBio Inc’s prices. A higher score indicates a more stable short-term price trend for AnaptysBio Inc.

How do we generate the institutional confidence score of AnaptysBio Inc?

To generate the institutional confidence score of AnaptysBio Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about AnaptysBio Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of AnaptysBio Inc.

How do we generate the risk management score of AnaptysBio Inc?

To assess the risk management score of AnaptysBio Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of AnaptysBio Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of AnaptysBio Inc.
KeyAI